Automated and Closed Cell Therapy Processing Systems Key Players | Innovation and Product Evolution | Market Entry and Expansion Strategies | Investment and Capital Allocation | Technology Commercialization | Market Trends Analysis | Future Market Positioning

Automated and Closed Cell Therapy Processing Systems Key Players-Business, Deal & Patent Strategies

The global market for automated and closed cell therapy processing systems is valued at USD 1.45 billion in 2024, rising to USD 1.74 billion in 2025. It is projected to reach approximately USD 8.86 billion by 2034, growing at a compound annual growth rate (CAGR) of 19.84% from 2025 to 2034.

Top Companies in the Automated and Closed Cell Therapy Processing Systems

• Beckman Coulter
• Bristol Myers Squibb
• Cellares, Inc.
• Cellular Origins
• Charles River Laboratories
• Cytiva Life Sciences
• Danaher Corporation
• Fresenius Kabi
• Miltenyi Biotec
• Multiply Labs
• Sartorius AG
• Sigma Aldrich
• Thermo Fisher Scientific
• Terumo Corporation

Recent Developments in the Automated And Closed Cell Therapy Processing Systems Market

• In October 2024, Terumo Blood and Cell Technologies announced the expansion of automated manufacturing of cell and gene therapy products to Latin American patients. The company adopted automation to collect, process, and separate blood and cells.
• In January 2024, Thermo Fisher Scientific announced the launch of Gibco Cell Therapy Systems (CTS) Cellmation Software that digitally connects instruments from its cell therapy portfolio to streamline and automate manufacturing.

Consignment Details of Medical Equipment and Supplies in the U.S.